Alexander I. Spira, MD, PhD, FACP - Breaking News in NSCLC: The Latest Evidence on Emerging Antibody Drug Conjugates Targeting TROP2

Please visit answersincme.com/DEV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses TROP2-directed therapies for patients with non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Outline the rationale for incorporating TROP2-directed therapies into the treatment of patients with advanced NSCLC; Explain the latest clinical data supporting the use of emerging TROP2-directed therapies in the treatment of advanced NSCLC; and Identify strategies to maximize the incorporation of TROP2-directed therapies into treatment plans for patients with advanced NSCLC, as they become available.